{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-25-000023","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.616304+00:00","generated_at":"2026-05-23T08:45:29.366658+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Boston Scientific Q1 sales $4.66B (+20.9% reported, +18.2% organic), EPS beat guidance","bullets":["GAAP EPS $0.45 (up 36% YoY); adjusted EPS $0.75, above guidance $0.66-0.68.","Cardiovascular segment sales grew 26.2% reported (25.6% organic); MedSurg +11.7% reported (+5.3% organic).","U.S. sales up 31.1%; EMEA +5.5%, APAC +8.2%, LACA +4.4%.","FY2025 outlook: organic +12-14%, adj. EPS $2.87-$2.94; Q2: organic +13-15%, adj. EPS $0.71-$0.73.","Closed Bolt Medical acquisition; agreed to acquire SoniVie Ltd. for TIVUS hypertension denervation technology."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-25-000023","json":"https://secwatch.observer/filing/0000885725-25-000023.json","markdown":"https://secwatch.observer/filing/0000885725-25-000023.md","text":"https://secwatch.observer/filing/0000885725-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/0000885725-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000023/bsx-20250423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:45:29.366658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}